Immunoprecise Antibodies Ltd Share Price Other OTC
Equities
CA87588T1030
Pharmaceuticals
Sales 2024 * | 24.59M 18.05M 1.42B | Sales 2025 * | 29.82M 21.89M 1.73B | Capitalization | 42.25M 31.02M 2.44B |
---|---|---|---|---|---|
Net income 2024 * | -12M -8.81M -694M | Net income 2025 * | -9M -6.61M -521M | EV / Sales 2024 * | 1.72 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 1.42 x |
P/E ratio 2024 * |
-3.36
x | P/E ratio 2025 * |
-4.56
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.41% |
Latest transcript on Immunoprecise Antibodies Ltd
Managers | Title | Age | Since |
---|---|---|---|
Jennifer Bath
CEO | Chief Executive Officer | - | 20/02/18 |
Kristin Taylor
DFI | Director of Finance/CFO | - | 28/09/23 |
Ilse Roodink
CTO | Chief Tech/Sci/R&D Officer | - | 30/06/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mitchell Levine
CHM | Chairman | - | - |
Chris Buyse
BRD | Director/Board Member | 59 | 04/09/23 |
Jennifer Bath
CEO | Chief Executive Officer | - | 20/02/18 |
1st Jan change | Capi. | |
---|---|---|
-2.32% | 90.45B | |
+3.68% | 41.45B | |
-10.90% | 33.57B | |
+58.05% | 25.73B | |
-19.56% | 14.73B | |
-9.06% | 12.82B | |
-11.34% | 11.7B | |
-43.53% | 11.44B | |
+3.75% | 8.79B |